Epilepsy Awareness and Grad School with University of New England
November 26, 2015
FOR IMMEDIATE RELEASE
Segment on Epilepsy Sponsored by Sunovion, and University of New England to Be Featured on November 27 on Lifetime®
(POMPANO BEACH, Fla. – PR LOG – November 25, 2015) Award-winning morning show The Balancing Act® will feature one segment that addresses raising awareness about epilepsy and managing the condition, and another segment focused on learning about both the undergraduate and graduate higher education experience. Tune in Friday, November 27 at 7:30 a.m. (ET/PT) on Lifetime® as The Balancing Act hosts help jump start the day with lively conversations and trusted information to empower a woman’s life.
Don’t miss these featured segments taking center stage on The Balancing Act:
Living with and Managing Epilepsy – sponsored by Sunovion
The statistics are stunning: 1 in 26 Americans are going to develop epilepsy at some point in their lifetime and about 3 million Americans are living with the condition. Join us to hear from Selim R. Benbadis, M.D. Professor and Director of the Comprehensive Epilepsy Program at the University of South Florida and Tampa General Hospital, and Kimberly, a graduate student who has been living with epilepsy her entire life. Dr. Benbadis will explain what epilepsy is, outline types of seizures, and discuss treatment options. Viewers will learn about Kimberly’s story and epilepsy journey, and how she manages the condition.
The segment is sponsored by Sunovion, a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives.
The Undergraduate and Graduate Campus Experience – with University of New England
Is graduate school for you? The University of New England, a private institution with a public mission, is a Health-Sciences University, grounded in the liberal arts. With two campuses in Maine and another one in Tangier, Morocco, it offers over 70 undergraduate, graduate and professional programs. The University of New England offers a variety of programs at the graduate and professional levels—including traditional campus-based programs and online programs. Ninety-percent of 2014 graduates are either employed of were accepted into graduate/professional programs. Whether you’re pursuing a graduate or professional degree in medicine, one of the allied health fields, the sciences, education, or any other discipline in which UNE specializes, you benefit from internationally renowned faculty, world-class facilities, and innovative programs that utilize the latest instructional methods and technologies. To learn more, visit: http:// www.une.edu
About The Balancing Act®
Entering its 8th season, The Balancing Act continues to empower women in all aspects of their lives. The mission at The Balancing Act is simple – to help today’s modern woman balance it all by bringing them positive solutions to enrich and empower them. Entertaining, educational and trusted by women, viewers can tune in to America’s premier morning show The Balancing Act on weekday mornings Monday through Friday at 7:30 am (ET/PT) on Lifetime television. For additional information or to view a segment visit: www.thebalancingact.com
Join the Conversation!
Like us on Facebook at: https://www.facebook.com/TheBalancingActFans
Follow us on Twitter at: http://twitter.com/balancingacttv
Watch us on YouTube at: http://www.youtube.com/thebalancingact
Bringing the best tips from the experts in Atlanta in business, beauty, wealth management, child healthcare, car shopping, and more. Each year, Atlanta’s Women’s Entrepreneurship Initiative selects 15 local female entrepreneurs for a 15-month business training program. We meet women who have grown their companies, created jobs, and broke through the glass ceiling. With some […]
iMCD is the deadliest subtype of Castleman disease. Approximately one third of patients die within five years of diagnosis, and another third die within 10 years if not treated.
There are no effective treatment options for people with unresectable or metastatic chondrosarcoma despite many attempts by multiple pharmaceutical companies over the past few decades.